Why is Marksans Pharma falling/rising?

As of 30-Jul, Marksans Pharma Ltd is experiencing a rise in its stock price, currently at 236.40, reflecting an increase of 8.85 or 3.89%. The stock has shown a positive performance today, outperforming its sector by 3.55% and achieving a consecutive gain over the last two days with a total return of 4.39%. Despite a recent decline of 9.65% over the past month and a year-to-date drop of 20.20%, the stock has demonstrated strong long-term performance, with a remarkable increase of 384.43% over the past three years. Factors contributing to this rise include high management efficiency indicated by a return on equity (ROE) of 17.66%, a low debt-to-equity ratio, and significant institutional holdings at 25.38%, which suggest confidence from more knowledgeable investors. However, concerns about poor long-term growth, as evidenced by a low operating profit growth rate and flat results in recent quarters, may temper enthusiasm.
In the broader market context, the stock's recent performance contrasts with the benchmark Sensex, which has declined by 1.50% over the past week and 2.54% over the past month. While Marksans Pharma has outperformed the benchmark in the short term, its year-to-date performance remains significantly lower than the Sensex's gain of 4.28%. This divergence highlights the stock's volatility and the mixed sentiment among investors, balancing between its recent gains and underlying concerns about long-term growth potential.